| Literature DB >> 35115835 |
Zhi-Jia Li1, Da-Ya Wang1, Zhi-Hu Liu2.
Abstract
OBJECTIVE: Bladder cancer is a common malignant tumor of the urinary system, with an incidence ranking the first in the urinary system. Without timely and effective treatment, the tumor may spread to other parts of the body. Traditional partial cystectomy (PC) and plasmakinetic transurethral resection of bladder tumor (PKRBT) are common surgical methods for superficial bladder cancer (SBC). This study aims to clarify the clinical efficacy of bladder carcinoma (BC) patients treated by either PC or PKRBT and their effects on the quality of life (QOL) of patients.Entities:
Keywords: PSQI; SAS; SDS; inflammatory factors; partial cystectomy; plasmakinetic transurethral resection of bladder tumor; superficial bladder cancer
Year: 2022 PMID: 35115835 PMCID: PMC8805739 DOI: 10.2147/CMAR.S346764
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
General Information
| Control Group (n=69) | Research Group (n=74) | χ2/t | P | |
|---|---|---|---|---|
| Gender [n(%)] | 0.01872 | 0.8912 | ||
| Male | 44 (63.77) | 48 (64.86) | ||
| Female | 25 (36.23) | 26 (35.14) | ||
| Average age (years) | 61.35±3.02 | 62.19±3.48 | 1.5368 | 0.1266 |
| BMI (kg/m2) | 21.45±1.38 | 21.69±1.51 | 0.9899 | 0.3239 |
| Course of disease (year) | 4.34±0.39 | 4.31±0.44 | 0.4303 | 0.6676 |
| Tumor diameter (cm) | 1.81±0.23 | 1.83±0.26 | 0.4858 | 0.6278 |
| Tumor staging | 0.4604 | 0.4974 | ||
| I | 40 (57.97) | 47 (63.51) | ||
| II | 29 (42.03) | 27 (36.49) | ||
| Pathological grading | 0.4178 | 0.5180 | ||
| G1 | 45 (65.22) | 52 (70.27) | ||
| G2 | 24 (34.78) | 22 (29.73) | ||
| Symptom | 1.0753 | 0.7831 | ||
| Odynuria | 31 (44.93) | 37 (50.00) | ||
| Incomplete bladder emptying | 18 (26.09) | 14 (18.92) | ||
| Sychnuria | 11 (15.94) | 13 (17.57) | ||
| Microscopic hematuria | 9 (13.04) | 10 (13.51) |
Clinical Indicators of Two Groups of Patients
| Intraoperative Blood Loss (mL) | Operating Time (min) | Bladder Irrigation Time (min) | Urinary Catheter Indwelling Time (d) | Postoperative Length of Hospital Stay (d) | |
|---|---|---|---|---|---|
| Control group (n=69) | 46.5±5.8 | 71.6±9.8 | 36.7±6.6 | 7.2±1.3 | 12.7±3.4 |
| Research group (n=74) | 23.7±3.5 | 45.3±5.6 | 16.7±4.3 | 4.6±0.7 | 6.9±2.1 |
| χ | 28.6802 | 19.8703 | 21.6113 | 15.0284 | 12.3634 |
| P |
Note: Data in bold indicates that the difference is statistically significant.
Figure 1Comparison of inflammatory factors between two groups. (A) TNF-α level; (B) IL-6 level; (C) IL-8 level; (D) IL-10 level; ***P<0.05.
Comparison of PSQI Scores Between Two Groups
| Before Operation | 7 Days After Operation | χ2/t | P | |
|---|---|---|---|---|
| Control group (n=69) | 8.68±2.14 | 5.06±1.63 | 11.1781 | |
| Research group (n=74) | 8.42±2.37 | 1.88±0.57 | 23.0799 | |
| χ | 0.6868 | 15.7827 | ||
| P | 0.4933 | |||
Note: Data in bold indicates that the difference is statistically significant.
Figure 2Comparison of SAS and SDS scores between two groups. (A) SAS score; (B) SDS score; ***P<0.05.
Comparison of Quality of Life Between Two Groups
| Control group (n=69) | 64.36±5.68 | 80.66±7.32 | 63.84±5.98 | 81.34±5.63 | 60.25±5.57 | 81.04±5.36 | 65.31±6.74 | 84.39±7.68 |
| Research group (n=74) | 65.02±6.49 | 83.74±6.59 | 64.38±6.13 | 84.67±6.19 | 61.17±5.72 | 84.31±6.11 | 65.76±7.05 | 87.83±7.49 |
| χ | 0.6452 | 2.6475 | 0.5326 | 3.3575 | 0.9733 | 3.4024 | 0.3896 | 2.7110 |
| P | 0.5198 | 0.5951 | 0.3321 | 0.6974 | ||||
| Control group (n=69) | 60.28±5.77 | 82.61±6.05 | 63.54±5.78 | 82.67±6.35 | 64.49±4.59 | 83.13±4.29 | 63.91±5.46 | 80.82±4.79 |
| Research group (n=74) | 61.03±6.41 | 85.57±5.39 | 64.19±5.94 | 84.93±5.71 | 64.80±4.82 | 85.74±4.49 | 64.22±5.99 | 83.47±5.10 |
| χ | 0.7335 | 3.0934 | 0.6624 | 2.2406 | 0.3933 | 3.5488 | 0.3227 | 3.1971 |
| P | 0.4644 | 0.5088 | 0.6947 | 0.7474 | ||||
Note: Data in bold indicates that the difference is statistically significant.
Incidence of Complications and One-Year Recurrence Rate
| Postoperative Infection | Cysthemorrhagia | Cystospasm | Urethrostenosis | Total Incidence | One-Year Recurrence Rate | |
|---|---|---|---|---|---|---|
| Control group (n=69) | 3 (4.35) | 5 (7.25) | 4 (5.80) | 3 (4.35) | 15 (21.74) | 32 (46.38) |
| Research group (n=74) | 1 (1.35) | 2 (2.70) | 2 (2.70) | 2 (2.70) | 7 (9.46) | 22(29.73) |
| χ | 4.1361 | 4.2101 | ||||
| P |
Note: Data in bold indicates that the difference is statistically significant.